title: Can we defeat meningococcal disease in low and middle income countries?
abstract: The development of multivalent conjugate and protein-based meningococcal vaccines may make global control of meningococcal disease possible. However, achieving control of meningococcal disease in low and middle income countries will be challenging. In low income countries whose vaccination programmes receive financial support from the Global Alliance for Vaccination and Immunisation, the main challenge is lack of sufficient epidemiological information to allow rational decisions on vaccine introduction to be made and, in these countries, enhanced surveillance is needed. In middle income countries, financial challenges predominate. These could be met by demonstration of the cost effectiveness of new meningococcal vaccines and through the introduction of a tiered-pricing system.
authors.affiliation: Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, Keppel St, London WC1E 7HT, UK. brian.greenwood@lshtm.ac.uk
authors.forename: Brian
authors.initials: B
authors.lastname: Greenwood
authors.forename: Emiliano
authors.initials: E
authors.lastname: Chiarot
authors.forename: Calman A
authors.initials: CA
authors.lastname: MacLennan
authors.forename: Miguel
authors.initials: M
authors.lastname: O'Ryan
mesh_terms: D003362:Cost-Benefit Analysis; D003906:Developing Countries; D006801:Humans; D017589:Immunization Programs / Q000191:economics* / Q000458:organization & administration*; D008589:Meningococcal Infections / Q000453:epidemiology* / Q000517:prevention & control*; D022401:Meningococcal Vaccines / Q000008:administration & dosage / Q000191:economics* / Q000276:immunology*
chemical_list: D022401:Meningococcal Vaccines